In a study examining tumor tissues, the loss of CDKN2A function, which is regulated by gene mutations, hemizygous or homozygous loss, and promoter methylation, can be distinguished in approximately 90% of oral SCCs [58]. The gene discussed is CDKN2A; the disease is neoplasm.